Suchergebnisse - Athena Philis‐Tsimikas

Treffer weiter einschränken
  1. 1
    Glycemic control among Latinos with type 2 diabetes: The role of social-environmental support resources.

    Glycemic control among Latinos with type 2 diabetes: The role of social-environmental support resources. von Addie L. Fortmann, Linda C. Gallo, Athena Philis‐Tsimikas

    Veröffentlicht 2011
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study

    Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study von Stephen R. Benoit, Regina K. Fleming, Athena Philis‐Tsimikas, Ming Ji

    Veröffentlicht 2005
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)

    Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use) von Athena Philis‐Tsimikas, Meryl Brod, Marcus Niemeyer, Ann Marie Ocampo Francisco, Jeffrey Rothman

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches

    Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches von Athena Philis‐Tsimikas, Adelaide Fortmann, Leticia Lleva-Ocana, Chris Walker, Linda C. Gallo

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    LDL Isolated From Greek Subjects on a Typical Diet or From American Subjects on an Oleate-Supplemented Diet Induces Less Monocyte Chemotaxis and Adhesion When Exposed to Oxidative Stress

    LDL Isolated From Greek Subjects on a Typical Diet or From American Subjects on an Oleate-Supplemented Diet Induces Less Monocyte Chemotaxis and Adhesion When Exposed to Oxidative... von Sotirios Tsimikas, Athena Philis‐Tsimikas, Sophoclis P. Alexopoulos, Farhad Sigari, Christian Lee, Peter D. Reaven

    Veröffentlicht 1999
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4

    Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to O... von Harpreet S. Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis‐Tsimikas, Tadej Battelino

    Veröffentlicht 2024
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes von Bernard Zinman, Athena Philis‐Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W. Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu

    Veröffentlicht 2012
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Improvement in Diabetes Care of Underinsured Patients Enrolled in Project Dulce

    Improvement in Diabetes Care of Underinsured Patients Enrolled in Project Dulce von Athena Philis‐Tsimikas, Chris Walker, Lisa Rivard, Gregory A. Talavera, Joachim O. F. Reimann, Michelle Salmon, Rachel A. Araujo

    Veröffentlicht 2004
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial

    Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial von Helena W. Rodbard, Bertrand Cariou, Bernard Zinman, Yehuda Handelsman, Athena Philis‐Tsimikas, Trine Vang Skjøth, Ashma Rana, Chantal Mathieu

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes

    Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes von Wendy Lane, Timothy S. Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis‐Tsimikas, Charlotte Thim Hansen, Thor S.S. Nielsen, Mark Warren

    Veröffentlicht 2017
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting

    Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting von Addie L. Fortmann, Samantha R. Spierling Bagsic, Laura Talavera, Isabel Maria Garcia, Haley Sandoval, Amiry Hottinger, Athena Philis‐Tsimikas

    Veröffentlicht 2020
    Volltext Volltext
    Carta
    Zu den Favoriten
    Gespeichert in:
  12. 12
    A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>)

    A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>) von Chantal Mathieu, Helena W. Rodbard, Bertrand Cariou, Yehuda Handelsman, Athena Philis‐Tsimikas, Ann Marie Ocampo Francisco, Ashma Rana, Bernard Zinman

    Veröffentlicht 2014
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northern Mexico

    Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northe... von María Cecilia Anzaldo-Campos, Sonia Contreras Contreras, Adriana Carolina Vargas-Ojeda, Rufino Menchaca-Díaz, Addie L. Fortmann, Athena Philis‐Tsimikas

    Veröffentlicht 2016
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial von Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones

    Veröffentlicht 2018
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes

    Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people... von Athena Philis‐Tsimikas, Liana K. Billings, Robert S. Busch, Cristóbal Morales, Rakesh Sahay, Natalie Halladin, S Eggert, Kamilla Begtrup, Stewart B. Harris

    Veröffentlicht 2019
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes

    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes von Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock

    Veröffentlicht 2022
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme

    Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme von Richard M. Bergenstal, Athena Philis‐Tsimikas, Carol Wysham, Molly C. Carr, Juliana Bue‐Valleskey, Fady T. Botros, Thomas Blevins, Julio Rosenstock

    Veröffentlicht 2024
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Cost‐Effectiveness of Diabetes Case Management for Low‐Income Populations

    Cost‐Effectiveness of Diabetes Case Management for Low‐Income Populations von Todd Gilmer, Stéphane Roze, William J. Valentine, Katrina Erny-Albrecht, Joshua Ray, D Cobden, L Nicklasson, Athena Philis‐Tsimikas, Andrew Palmer

    Veröffentlicht 2007
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

    Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial von Athena Philis‐Tsimikas, David C. Klonoff, Kamlesh Khunti, Harpreet S. Bajaj, Lawrence A. Leiter, M. Hansen, Lone Troelsen, Steen Ladelund, Simon Heller, Thomas R. Pieber

    Veröffentlicht 2020
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

    Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized,... von David Russell‐Jones, Bruce W. Bode, Christophe De Block, Edward Franek, Simon Heller, Chantal Mathieu, Athena Philis‐Tsimikas, Ludger Rose, Vincent Woo, Anne Birk Østerskov, Tina Graungaard, Richard M. Bergenstal

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: